TSNA exposure from cigarette smoking: 18Years of urinary NNAL excretion data

Regulatory Toxicology and Pharmacology

Volumn 68, Issue 2, 2014, Pages 269-274

  Appleton, Scott ^a   Olegario, Raquel M ^a   Lipowicz, Peter J ^a  

^a Altria Client Services Inc   (United States)

Author keywords

Cigarettes; NNAL; NNK; NNN; Tobacco products; Tobacco specific nitrosamines (TSNA)

Indexed keywords

CIGARETTES; NNAL; NNK; NNN; TOBACCO PRODUCTS; TOBACCO SPECIFIC NITROSAMINES (TSNA);

HUMANS; NITROSAMINES; PYRIDINES; SMOKE; SMOKING; TOBACCO INDUSTRY; TOBACCO PRODUCTS; UNITED STATES;

EID: 84893756275     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2013.07.013     Document Type: Article

References (60)

1. Anderson K.E., Carmella S.G., Ye M., Bliss R.L., Le C., Murphy L., Hecht S.S. Metabolites of a tobacco-specific lung carcinogen in nonsmoking women exposed to environmental tobacco smoke. J. Natl. Cancer Inst. 2001, 93:378-381.
2. Appleton S., Olegario R.M., Lipowicz P.J. TSNA levels in machine-generated mainstream cigarette smoke: 35years of data. Regul. Toxicol. Pharmacol. 2013, 66:197-207.
3. Ashley D.L., O'Connor R.J., Bernert J.T., Watson C.H., Polzin G.M., Jain R.B., Hammond D., Hatsukami D.K., Giovino G.A., Cummings K.M., McNeill A., Shahab L., King B., Fong G.T., Zhang L., Xia Y., Yan X., McCraw J.M. Effect of differing levels of tobacco-specific nitrosamines in cigarette smoke on the levels of biomarkers in smokers. Cancer Epidemiol. Biomarkers Prev. 2010, 19:1389-1398.
4. Benowitz N.L., Jacob P., Bernert J.T., Wilson M., Wang L., Allen F., Dempsey D. Carcinogen exposure during short-term switching from regular to "light" cigarettes. Cancer Epidemiol. Biomarkers Prev. 2005, 14:1376-1383.
5. Benowitz N., Goniewicz M.L., Eisner M.D., Lazcano-Ponce E., Zielinska-Danch W., Koszowski B., Sobczak A., Havel C., Jacob P. Urine cotinine underestimates exposure to the tobacco-derived lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in passive compared with active smokers. Cancer Epidemiol. Biomarkers Prev. 2010, 19:2795-2800.
6. Benowitz N.L., Dains K.M., Dempsey D., Havel C., Wilson M., Jacob P. Urine menthol as a biomarker of mentholated cigarette smoking. Cancer Epidemiol. Biomarkers Prev. 2010, 19:3013-3019.
7. Benowitz N.L., Dains K.M., Hall S.M., Stewart S., Wilson M., Dempsey D., Jacob P. Smoking behavior and exposure to tobacco toxicants during 6months of smoking progressively reduced nicotine content cigarettes. Cancer Epidemiol. Biomarkers Prev. 2012, 21:761-769.
8. Benowitz N.L., Renner C.C., Lanier A.P., Tyndale R.F., Hatsukami D.K., Lindgren B., Stepanov I., Watson C.H., Sosnoff C.S., Jacob P. Exposure to nicotine and carcinogens among Southwestern Alaskan Native cigarette smokers and smokeless tobacco users. Cancer Epidemiol. Biomarkers Prev. 2012, 21:934-942.
9. Bernert J.T., Pirkle J.L., Xia Y., Jain R.B., Ashley D.L., Sampson E.J. Urine concentrations of a tobacco-specific nitrosamine carcinogen in the US population from secondhand smoke exposure. Cancer Epidemiol. Biomarkers Prev. 2010, 19:2969-2977.
10. Blank M.D., Eissenberg T. Evaluating oral noncombustible potential-reduced exposure products for smokers. Nicotine Tob. Res. 2010, 12:336-343.
11. Breland A.B., Acosta M.C., Eissenberg T. Tobacco specific nitrosamines and potential reduced exposure products for smokers: a preliminary evaluation of advance. Tob. Control 2003, 12:317-321.
12. Burns D.M., Dybing E., Gray N., Hecht S., Anderson C., Sanner T., O'Connor R., Djordjevic M., Dresler C., Hainaut P., Jarvis M., Opperhuizen A., Straif K. Mandated lowering of toxicants in cigarette smoke: a description of the World Health Organization TobReg proposal. Tob. Control 2008, 17:132-141.
13. Carmella S.G., Akerkar S., Hecht S.S. Metabolites of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in smokers' urine. Cancer Res. 1993, 53:721-724.
14. Carmella S.G., Akerkar S.A., Richie J.P., Hecht S.S. Intraindividual and interindividual differences in metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers' urine. Cancer Epidemiol. Biomarkers Prev. 1995, 4:635-642.
15. Carmella S.G., Borukhova A., Akerkar S.A., Hecht S.S. Analysis of human urine for pyridine-N-oxide metabolites of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco-specific lung carcinogen. Cancer Epidemiol. Biomarkers Prev. 1997, 6:113-120.
16. Carmella S.G., Han S., Fristad A., Yang Y., Hecht S.S. Analysis of total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human urine. Cancer Epidemiol. Biomarkers Prev. 2003, 12:1257-1261.
17. Carmella S.G., Chen M., Han S., Briggs A., Jensen J., Hatsukami D.K., Hecht S.S. Effects of smoking cessation on eight urinary tobacco carcinogen and toxicant biomarkers. Chem. Res. Toxicol. 2009, 22:734-741.
18. Church T.R., Anderson K.E., Le C., Zhang Y., Kampa D.M., Benoit A.R., Yoder A.R., Carmella S.G., Hecht S.S. Temporal stability of urinary and plasma biomarkers of tobacco smoke exposure among cigarette smokers. Biomarkers 2010, 15:345-352.
19. Derby K.S., Cuthrell K., Caberto C., Carmella S., Murphy S.E., Hecht S.S., Le M.L. Exposure to the carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers from 3 populations with different risks of lung cancer. Int. J. Cancer 2009, 125:2418-2424.
20. Frost-Pineda K., Zedler B.K., Oliveri D., Feng S., Liang Q., Roethig H.J. Short-term clinical exposure evaluation of a third-generation electrically heated cigarette smoking system (EHCSS) in adult smokers. Regul. Toxicol. Pharmacol. 2008, 52:104-110.
21. Goniewicz M.L., Havel C.M., Peng M.W., Jacob P., Dempsey D., Yu L., Zielinska-Danch W., Koszowski B., Czogala J., Sobczak A., Benowitz N.L. Elimination kinetics of the tobacco-specific biomarker and lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol. Cancer Epidemiol. Biomarkers Prev. 2009, 18:3421-3425.
22. Hatsukami D.K., Lemmonds C., Zhang Y., Murphy S.E., Le C., Carmella S.G., Hecht S.S. Evaluation of carcinogen exposure in people who used "reduced exposure" tobacco products. J. Natl. Cancer Inst. 2004, 96:844-852.
23. Hatsukami D., Mooney M., Murphy S., LeSage M., Babb D., Hecht S. Effects of high dose transdermal nicotine replacement in cigarette smokers. Pharmacol. Biochem. Behav. 2007, 86:132-139.
24. Hatsukami D.K., Kotlyar M., Hertsgaard L.A., Zhang Y., Carmella S.G., Jensen J.A., Allen S.S., Shields P.G., Murphy S.E., Stepanov I., Hecht S.S. Reduced nicotine content cigarettes: effects on toxicant exposure, dependence and cessation. Addiction 2010, 105:343-355.
25. Hecht S.S., Chung F.L., Richie J.P., Akerkar S.A., Borukhova A., Skowronski L., Carmella S.G. Effects of watercress consumption on metabolism of a tobacco-specific lung carcinogen in smokers. Cancer Epidemiol. Biomarkers Prev. 1995, 4:877-884.
26. Hecht S.S., Carmella S.G., Chen M., Dor Koch J.F., Miller A.T., Murphy S.E., Jensen J.A., Zimmerman C.L., Hatsukami D.K. Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation. Cancer Res. 1999, 59:590-596.
27. Hecht S.S. Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. Carcinogenesis 2002, 23:907-922.
28. Hecht S.S., Carmella S.G., Murphy S.E., Riley W.T., Le C., Luo X., Mooney M., Hatsukami D.K. Similar exposure to a tobacco-specific carcinogen in smokeless tobacco users and cigarette smokers. Cancer Epidemiol. Biomarkers Prev. 2007, 16:1567-1572.
29. Heck J.D. Smokers of menthol and nonmenthol cigarettes exhibit similar levels of biomarkers of smoke exposure. Cancer Epidemiol. Biomarkers Prev. 2009, 18:622-629.
30. Hughes J.R., Hecht S.S., Carmella S.G., Murphy S.E., Callas P. Smoking behaviour and toxin exposure during six weeks use of a potential reduced exposure product: Omni. Tob. Control 2004, 13:175-179.
31. Hurt R.D., Croghan G.A., Wolter T.D., Croghan I.T., Offord K.P., Williams G.M., Djordjevic M.V., Richie J.P., Jeffrey A.M. Does smoking reduction result in reduction of biomarkers associated with harm? A pilot study using a nicotine inhaler. Nicotine Tob. Res. 2000, 2:327-336.
32. IARC, 2007. IARC monographs on the evaluation of carcinogenic risks to humans, vol. 89. Smokeless tobacco and some tobacco-specific N-nitrosamines. (accessed July 2013). http://monographs.iarc.fr/ENG/Monographs/vol89/mono89.pdf.
33. IARC, 2009. IARC monographs on the evaluation of carcinogenic risks to humans, vol. 100 E. A review of human carcinogens. Personal habits and indoor combustions. (accessed July 2013). http://monographs.iarc.fr/ENG/Monographs/vol100E/mono100E.pdf.
34. Jones M.R., Apelberg B.J., Tellez-Plaza M., Samet J.M., Navas-Acien A. Menthol cigarettes, race/ethnicity, and biomarkers of tobacco use in US adults: the 1999-2010 National Health and Nutrition Examination Survey (NHANES). Cancer Epidemiol. Biomarkers Prev. 2013, 22:224-232.
35. Joseph A.M., Hecht S.S., Murphy S.E., Carmella S.G., Le C.T., Zhang Y., Han S., Hatsukami D.K. Relationships between cigarette consumption and biomarkers of tobacco toxin exposure. Cancer Epidemiol. Biomarkers Prev. 2005, 14:2963-2968.
36. Khariwala S.S., Carmella S.G., Stepanov I., Fernandes P., Lassig A.A., Yueh B., Hatsukami D., Hecht S.S. Elevated levels of 1-hydroxypyrene and N'-nitrosonornicotine in smokers with head and neck cancer: a matched control study. Head Neck 2012, http://dx.doi.org/10.1002/hed.23085.
37. Kinser, R.D., Nelson, B.L., Roethig, H.J., Walk, R.A., Oey, J., Tricker, A.R., Leyden, D.E., 2002. Use of nicotine and NNK metabolites to assess exposure to cigarette smoke constituents: pilot study results. Poster Presented at the 8th Annual Meeting of the Society for Research on Nicotine and Tobacco, Savannah, GA, February 20-23, 2002.
38. Le Marchand L., Derby K.S., Murphy S.E., Hecht S.S., Hatsukami D., Carmella S.G., Tiirikainen M., Wang H. Smokers with the CHRNA lung cancer-associated variants are exposed to higher levels of nicotine equivalents and a carcinogenic tobacco-specific nitrosamine. Cancer Res. 2008, 68:9137-9140.
39. Melikian A.A., Djordjevic M.V., Chen S., Richie J., Stellman S.D. Effect of delivered dosage of cigarette smoke toxins on the levels of urinary biomarkers of exposure. Cancer Epidemiol. Biomarkers Prev. 2007, 16:1408-1415.
40. Mendoza-Baumgart M.I., Tulunay O.E., Hecht S.S., Zhang Y., Murphy S., Le C., Jensen J., Hatsukami D.K. Pilot study on lower nitrosamine smokeless tobacco products compared with medicinal nicotine. Nicotine Tob. Res. 2007, 9:1309-1323.
41. Current cigarette smoking among adults - United States, 2011. MMWR Morb. Mortal. Wkly. Rep. 2012, 61:889-894. MMWR.
42. Murphy S.E., Link C.A., Jensen J., Le C., Puumala S.S., Hecht S.S., Carmella S.G., Losey L., Hatsukami D.K. A comparison of urinary biomarkers of tobacco and carcinogen exposure in smokers. Cancer Epidemiol. Biomarkers Prev. 2004, 13:1617-1623.
43. Muscat J.E., Djordjevic M.V., Colosimo S., Stellman S.D., Richie J.P. Racial differences in exposure and glucuronidation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Cancer 2005, 103:1420-1426.
44. Muscat J.E., Chen G., Knipe A., Stellman S.D., Lazarus P., Richie J.P. Effects of menthol on tobacco smoke exposure, nicotine dependence, and NNAL glucuronidation. Cancer Epidemiol. Biomarkers Prev. 2009, 18:35-41.
45. Roethig H.J., Feng S., Liang Q., Liu J., Rees W.A., Zedler B.K. A 12-month, randomized, controlled study to evaluate exposure and cardiovascular risk factors in adult smokers switching from conventional cigarettes to a second-generation electrically heated cigarette smoking system. J. Clin. Pharmacol. 2008, 48:580-591.
46. Roethig H.J., Munjal S., Feng S., Liang Q., Sarkar M., Walk R.A., Mendes P.E. Population estimates for biomarkers of exposure to cigarette smoke in adult US cigarette smokers. Nicotine Tob. Res. 2009, 11:1216-1225.
47. Rostron B. NNAL exposure by race and menthol cigarette use among US smokers. Nicotine Tob. Res. 2013, 15:950-956.
48. Sarkar M., Kapur S., Frost-Pineda K., Feng S., Wang J., Liang Q., Roethig H. Evaluation of biomarkers of exposure to selected cigarette smoke constituents in adult smokers switched to carbon-filtered cigarettes in short-term and long-term clinical studies. Nicotine Tob. Res. 2008, 10:1761-1772.
49. Sarkar M., Liu J., Koval T., Wang J., Feng S., Serafin R., Jin Y., Xie Y., Newland K., Roethig H.J. Evaluation of biomarkers of exposure in adult cigarette smokers using Marlboro snus. Nicotine Tob. Res. 2010, 12:105-116.
50. Sellers E.M., Ramamoorthy Y., Zeman M.V., Djordjevic M.V., Tyndale R.F. The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo. Nicotine Tob. Res. 2003, 5:891-899.
51. St. Helen G., Goniewicz M.L., Dempsey D., Wilson M., Jacob P., Benowitz N.L. Exposure and kinetics of polycyclic aromatic hydrocarbons (PAHs) in cigarette smokers. Chem. Res. Toxicol. 2012, 25:952-964.
52. Stepanov I., Hecht S.S. Tobacco-specific nitrosamines and their pyridine-N-glucuronides in the urine of smokers and smokeless tobacco users. Cancer Epidemiol. Biomarkers Prev. 2005, 14:885-891.
53. Stepanov I., Hecht S.S., Lindgren B., Jacob P., Wilson M., Benowitz N.L. Relationship of human toenail nicotine, cotinine, and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol to levels of these biomarkers in plasma and urine. Cancer Epidemiol. Biomarkers Prev. 2007, 16:1382-1386.
54. Stepanov I., Upadhyaya P., Carmella S.G., Feuer R., Jensen J., Hatsukami D.K., Hecht S.S. Extensive metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in smokers. Cancer Epidemiol. Biomarkers Prev. 2008, 17:1764-1773.
55. Stepanov I., Carmella S.G., Han S., Pinto A., Strasser A.A., Lerman C., Hecht S.S. Evidence for endogenous formation of N'-nitrosonornicotine in some long-term nicotine patch users. Nicotine Tob. Res. 2009, 11:99-105.
56. Strasser A.A., Benowitz N.L., Pinto A.G., Tang K.Z., Hecht S.S., Carmella S.G., Tyndale R.F., Lerman C.E. Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level. Cancer Epidemiol. Biomarkers Prev. 2011, 20:234-238.
57. Taioli E., Garbers S., Bradlow H.L., Carmella S.G., Akerkar S., Hecht S.S. Effects of indole-3-carbinol on the metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in smokers. Cancer Epidemiol. Biomarkers Prev. 1997, 6:517-522.
58. Ter-Minassian M., Asomaning K., Zhao Y., Chen F., Su L., Carmella S.G., Lin X., Hecht S.S., Christiani D.C. Genetic variability in the metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL). Int. J. Cancer 2012, 130:1338-1346.
59. USDHHS, 2010. A report of the Surgeon General: How tobacco smoke causes disease, 2010. The biology and behavioral basis for smoking-attributable disease. (accessed July 2013). http://www.surgeongeneral.gov/library/reports/tobaccosmoke/report-index.html.
60. USDHHS, 2012. US Food and Drug Administration. Harmful and potentially harmful constituents in tobacco products and tobacco smoke: established list. (accessed July 2013). http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297786.htm.